CVS Health stock: RBC set a USD 113.00 target for CVS Health stock

Published on 10/20/2026 at 17:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health reports results on November 4, 2026. CVS Health stock costs EUR 83.97 on October 20, 2026, up 2.85 percent versus the Xetra close.

Analyst target and reporting date

On October 7, 2026, RBC set a USD 113.00 target for CVS Health.
CVS Health will discuss third-quarter 2026 results on November 4, 2026.
CVS Health stock costs EUR 83.97 at Lang & Schwarz on October 20, 2026 at 5:12 p.m. CEST, 2.85 percent above the Xetra close of October 19, 2026, and 13.35 percent below the 52-week high.
CVS Health has a USD 120.7 billion market capitalization and a 24.99 price-to-earnings ratio as of October 20, 2026.

Fotorealistisches CGI-Rendering eines modernen Glas-Stahl-Bürogebäudes mit Grünanlage — CVS Health Corp. modernes Unternehmensgebäude als Architektur-Render mit moderner Glas-Stahl-Fassade, ISIN US1266501006, Illustration mit AI erstellt.

RBC Capital analyst Ben Hendrix maintained a Buy rating and set a USD 113.00 target for CVS Health on October 7, 2026, according to Markets Insider. The target is 19.76 percent above the USD 94.36 primary-exchange price dated October 20, 2026 at 11:26 a.m. ET. At Lang & Schwarz, the stock was trading at EUR 83.97 on October 20, 2026 at 5:12 p.m. CEST, up 2.85 percent versus the Xetra close of October 19, 2026 at EUR 81.64.

Results date sets the next checkpoint

CVS Health will discuss its third-quarter 2026 financial results on November 4, 2026, at 8:00 a.m. ET. The date was announced on October 5, 2026, in a company release carried by CVS Health. The appointment gives investors a defined point for testing the USD 113.00 target against new operating figures.

Stock sits below its yearly high

The primary-exchange 52-week range is USD 69.51 to USD 110.68 as of October 20, 2026. The EUR 83.97 Lang & Schwarz price is 13.35 percent below the USD 110.68 high when measured in the same euro-denominated quote range, while the company has a USD 120.7 billion market capitalization. Trading volume stood at 1,480,839 shares at 11:26 a.m. ET.

Valuation and upcoming dates

CVS Health traded at a 24.99 price-to-earnings ratio and carried a 3.00 percent dividend yield on October 20, 2026. The company describes its business as a combination of health services, health insurance, pharmacy operations and prescription drug coverage. Its next scheduled corporate date is the November 4, 2026 results conference.

Comparison with peers

CVS Health Corp.: up 2.85 percent versus the Xetra close, price-to-earnings ratio 24.99, market capitalization USD 120.7 billion, based on October 20, 2026 values. Humana: up 2.91 percent, price-to-earnings ratio 40.50, market capitalization USD 51.3 billion, based on October 20, 2026 values. Cigna: up 2.29 percent, price-to-earnings ratio 12.66, market capitalization USD 80.7 billion, based on October 20, 2026 values.

Target and price in perspective

RBC's USD 113.00 target sits above the primary-exchange price, while the Lang & Schwarz quote remains below its 52-week high. The scheduled results date is the next concrete test for the assumptions behind the analyst view.

The stock was trading at EUR 83.97 at Lang & Schwarz on October 20, 2026 at 5:12 p.m. CEST, 2.85 percent above the Xetra close of October 19, 2026 at EUR 81.64. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.